Clinical trial · Interventional
PSMA-PET Imaging for Advanced ACC/SDC
68Ga-PSMA-PET/CT Imaging for Locally Advanced, Recurrent and Metastatic Adenoid Cystic Carcinoma or Salivary Duct Carcinoma
NCT03319641CI-TRIAL-00033135completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Diagnostic study which evaluates the level of PSMA expression in patients with locally advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are eligible for 177Lu-PSMA therapy
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenoid Cystic Carcinoma | Adenoid Cystic Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Salivary Duct Carcinoma | Salivary Duct Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Salivary Gland Cancer | Malignant Salivary Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PSMA-PET/CT scan | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PSMA-PET/CT scan
- description
- PSMA-PET/CT imaging in advanced ACC/SDC
- interventionNames
- Diagnostic Test: PSMA-PET/CT scan
Primary outcomes (1)
- measure
- uptake of 68Ga-PSMA in ACC and SDC
- timeFrame
- 0 days
- description
- To evaluate the uptake of 68Ga-PSMA in locally advanced, recurrent and metastatic ACC/SDC by performing 68Ga-PSMA-PET/CT scans
Secondary outcomes (4)
- measure
- SUV of 68Ga-PSMA in ACC/SDC tumors
- timeFrame
- 0 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * locally advanced, recurrent or metastatic ACC/SDC * Age ≥ 18 years old * Ability to provide written informed consent Exclusion Criteria: * Contra-indication for PET imaging * Pregnancy * Breast feeding * Severe claustrophobia * Impaired renal function: MDRD \<30 ml/min/1,73 m2 * Impaired liver function: AST and ALT ≥ 2.5 x ULN (≥5 x ULN for patients with liver metastases)
References
Publications (0)
Data not yet available
No reference posted for this study.